• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards

    2/3/26 7:12:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QDEL alert in real time by email

    – First medical device company to receive excellence recognition in accordance with ISO 23592

    – Gold Stevie® Award for Customer Service Success

    – Bronze Stevie® Award for AI & Tech Focused Digital Transformation Team of the Year

    SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho") received the Excellence Services Label for its Customer and Technical Services in EMEA, awarded by the independent association Esprit de Service France, and in accordance with the international standard ISO 23592, a global framework for designing and delivering outstanding customer experiences. QuidelOrtho is the first medical device company to receive this distinction.

    Excellence Services Label

    QuidelOrtho also won a Gold Stevie Award in the Customer Service Success category and a Bronze Stevie Award in the AI & Tech Focused Digital Transformation Team of the Year category in the 20th annual Stevie Awards for Sales & Customer Service.

    These awards underscore the customer experience at QuidelOrtho, which is designed to be predictive, connected, intelligent and grounded in the QuidelOrthoCQ™ Philosophy of turning intelligence and ease into care customers can feel.

    "These 2026 recognitions are a testament to the passion and discipline of our teams across the globe," said Karen Taylor, Senior Vice President, Customer Experience, QuidelOrtho. "Achieving the Excellence Services Label reflects not only our commitment to customer-centricity, but also the strength of our quality management system, processes, training and culture of continuous improvement. Earning both the Gold and Bronze Stevie Awards further reflects the strength of our customer‑first approach and our ability to harness innovation, technology and teamwork to deliver meaningful improvements in service."

    ISO 23592, first published in 2021, provides organizations with guidance to build customer-centric systems that go beyond basic expectations to deliver memorable, high-quality experiences across every touchpoint. While ISO 23592 is not yet a certifiable standard, the Excellence Services Label affirms that the organization has been evaluated in accordance with ISO 23592 requirements and has demonstrated maturity, innovation and consistent customer focus. The certification scope spans Customer Service, the Technical Solutions Center, Technical Training, and Field Service, supporting a unified service model designed to deliver consistent value throughout the customer journey.

    The Stevie Awards for Sales & Customer Service are the world's top honors for customer service, contact center, business development and sales professionals. The Stevie Awards organize nine of the world's leading business awards programs, including the prestigious American Business Awards® and International Business Awards®.

    Strengthening customer trust

    The Excellence Services Label provides customers across the region with a trusted, third‑party‑validated assurance of QuidelOrtho's commitment to delivering high-quality, consistent service experience. While the label does not directly change operational processes, it validates the systems, methods and culture that underpin exceptional support, training, problem‑solving and overall service reliability.

    QuidelOrthoCQ, or Care Quotient, is QuidelOrtho's company-wide program designed to reflect its customers' beliefs and values, brought to life through QuidelOrtho's people and the solutions they create. It is the measure of the level of care, empathy and compassion QuidelOrtho has for their customers and their customers' experience working with QuidelOrtho.

    To learn more about QuidelOrtho's commitment to its customer experience, listen to this episode of Repertoire Magazine Podcast with Karen Taylor, where she discusses the QuidelOrthoCQ Customer Experience Program.

    QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.

    About QuidelOrtho Corporation

    With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (NASDAQ:QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

    About the Excellence Services Label & ISO 23592

    The Excellence Services Label is issued by Esprit de Service France, an independent association specializing in customer experience maturity assessments and audits. The label confirms that the evaluated organization has implemented tools, frameworks and cultural practices aligned with ISO 23592 and has demonstrated a commitment to innovation and continuous improvement in customer experiences.

    About The Stevie® Awards

    Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Sales & Customer Service, the Stevie Awards for Technology Excellence, and the Stevie Awards for Women in Business. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations and territories. More than 1,000 professionals around the world participate in the Stevie Awards judging process each year. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

    Source: QuidelOrtho Corporation

    Investor Contact:

    Juliet Cunningham

    Vice President, Investor Relations

    IR@QuidelOrtho.com

    Media Contact:

    D. Nikki Wheeler

    Senior Director, Corporate Communications

    media@QuidelOrtho.com

    Excellence Services Awards Team Photo

    Gold Stevie® Award for Customer Service Success

    Bronze Stevie® Award for AI & Tech Focused Digital Transformation Team of the Year

    QuidelOrtho Corporation (PRNewsfoto/QuidelOrtho Corporation)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-receives-excellence-services-label-in-emea-and-two-stevie-awards-302676865.html

    SOURCE QuidelOrtho Corporation

    Get the next $QDEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QDEL

    DatePrice TargetRatingAnalyst
    10/7/2025$33.00Buy → Neutral
    Citigroup
    5/8/2025$44.00Hold → Buy
    Jefferies
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    12/10/2024$43.00Hold
    Jefferies
    9/19/2024$42.00 → $50.00Neutral
    UBS
    9/5/2024$40.00 → $57.00Hold → Buy
    Craig Hallum
    3/4/2024$70.00 → $42.00Neutral → Sell
    UBS
    2/14/2024$66.00 → $37.00Neutral → Underweight
    JP Morgan
    More analyst ratings

    $QDEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards

    – First medical device company to receive excellence recognition in accordance with ISO 23592– Gold Stevie® Award for Customer Service Success– Bronze Stevie® Award for AI & Tech Focused Digital Transformation Team of the Year SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho") received the Excellence Services Label for its Customer and Technical Services in EMEA, awarded by the independent association Esprit de Service France, and in accordance with the international standard ISO 23592, a global framework for designing and delivering outstanding customer experiences. QuidelOrtho is the first medical device company to receive this distinction.

    2/3/26 7:12:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Strengthening the blood supply: Awareness, challenges and donor impact

    SAN DIEGO, Jan. 22, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in in vitro diagnostics, has released episode 55 of its Science Bytes podcast, featuring Michelle Mullens, Global Portfolio Marketing Manager for Transfusion Medicine. With decades of experience in blood banking and immunohematology, Mullens shares insights into the pressures on today's blood supply and the importance of consistent donor engagement. Key insights: Everyday and climate-driven emergencies strain supply: Routine trauma, traffic injuries and increasingly frequent weather

    1/22/26 7:12:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results

    SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the fourth quarter and full year 2025 ended December 28, 2025, after the market close on Wednesday, February 11, 2026. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "

    1/21/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    SEC Filings

    View All

    SEC Form 8-K filed by QuidelOrtho Corporation

    8-K - QuidelOrtho Corp (0001906324) (Filer)

    2/5/26 4:19:16 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation

    SCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    2/5/26 1:36:41 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 144 filed by QuidelOrtho Corporation

    144 - QuidelOrtho Corp (0001906324) (Subject)

    11/25/25 4:11:45 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rhoads Ann D bought $21,206 worth of shares (750 units at $28.27), increasing direct ownership by 5% to 15,021 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    12/10/25 6:37:17 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Wilkins Joseph D Jr. bought $10,343 worth of shares (370 units at $27.95), increasing direct ownership by 3% to 11,876 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    12/1/25 4:33:10 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Busky Joseph M. bought $124,305 worth of shares (4,770 units at $26.06) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    11/25/25 1:21:09 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Human Resources Officer Bowman Ronald Lee

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/3/26 7:51:39 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by EVP of R&D & CTO Siegrist Jonathan Philip

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/3/26 7:50:22 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Operations Officer Mclellan Philip D. was granted 4,617 shares and covered exercise/tax liability with 1,627 shares, increasing direct ownership by 18% to 19,174 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/3/26 7:51:02 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    QuidelOrtho downgraded by Citigroup with a new price target

    Citigroup downgraded QuidelOrtho from Buy to Neutral and set a new price target of $33.00

    10/7/25 8:58:45 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho upgraded by Jefferies with a new price target

    Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00

    5/8/25 9:44:58 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho upgraded by Citigroup with a new price target

    Citigroup upgraded QuidelOrtho from Neutral to Buy and set a new price target of $50.00 from $44.00 previously

    12/11/24 8:21:07 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Leadership Updates

    Live Leadership Updates

    View All

    QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

    SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to President and Chief Executive Officer Brian Blaser, and he will lead the Company's enterprise strategy, business development, government affairs and portfolio management functions. Mr. Wolff brings over two decades of leadership experience in strategy, M&A and business development across the heal

    8/19/25 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    QuidelOrtho Announces New R&D Executive Leader

    Jonathan Siegrist appointed as EVP of R&D and CTO QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective as of October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009251239/en/Jonathan Siegrist, EVP of R&D and CTO, QuidelOrtho (Photo: Business Wire) Siegrist brings a wealth of industry expertise and leadership experience with over 15 years in molecular diagnostics, microfluidic platforms, and biomedi

    10/9/24 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    12/6/24 10:11:24 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

    11/21/24 5:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    11/14/24 1:28:35 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Financials

    Live finance-specific insights

    View All

    QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results

    SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the fourth quarter and full year 2025 ended December 28, 2025, after the market close on Wednesday, February 11, 2026. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "

    1/21/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Reports Third Quarter 2025 Financial Results

    ― Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ― ― Successful completion of debt refinancing, enhancing financial flexibility through improved terms and reduced amortization obligations ― ― Full-year 2025 revenue and adjusted EBITDA guidance ranges narrowed; adjusted diluted EPS updated to reflect debt refinancing ―  Third Quarter 2025 Results(all comparisons are to the prior year period)                                   Total revenue was $700 million, as reportedNon-respiratory revenue was $588 million, an increase of 5% as reported and 4% in constant currency; excluding Donor S

    11/5/25 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho to Report Third Quarter 2025 Financial Results

    SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the third quarter 2025 ended September 28, 2025, after the market closes on Wednesday, November 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relat

    10/22/25 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care